Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden flag Sweden · Delayed Price · Currency is SEK
1.410
-0.055 (-3.75%)
May 6, 2026, 5:22 PM CET

STO:NEWBRY Income Statement

Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Feb '26 Aug '25 Aug '24 Aug '23 Aug '22 Aug '21
32.7831.5736.8310.275.523.09
Revenue Growth (YoY)
-20.99%-14.27%258.75%86.11%78.73%-
Cost of Revenue
24.118.7420.86.323.952.58
Gross Profit
8.6712.8316.033.951.560.5
Selling, General & Admin
27.3327.7728.7720.8114.665.95
Other Operating Expenses
-0.19----0.12-0.01
Operating Expenses
32.9333.4430.522.0715.556.6
Operating Income
-24.25-20.61-14.47-18.12-13.99-6.1
Interest Expense
-1.66-1.65-1.53---0.04
Interest & Investment Income
0.020.020.20.16-0.11
Currency Exchange Gain (Loss)
-0.81-0.810.39-1.47-0.68-0.03
EBT Excluding Unusual Items
-27.66-23.06-15.41-19.43-14.67-6.06
Gain (Loss) on Sale of Assets
-0.55-0.55----
Pretax Income
-28.2-23.6-15.41-19.43-14.67-6.06
Income Tax Expense
0.280.28-0---
Net Income
-28.48-23.88-15.41-19.43-14.67-6.06
Net Income to Common
-28.48-23.88-15.41-19.43-14.67-6.06
Shares Outstanding (Basic)
2926212018-
Shares Outstanding (Diluted)
2926212018-
Shares Change (YoY)
21.93%21.08%9.68%9.68%--
EPS (Basic)
-0.98-0.92-0.72-1.00-0.82-
EPS (Diluted)
-0.98-0.92-0.72-1.00-0.82-
Gross Margin
26.46%40.63%43.53%38.46%28.35%16.26%
Operating Margin
-74.00%-65.27%-39.29%-176.51%-253.57%-197.67%
Profit Margin
-86.91%-75.65%-41.83%-189.28%-265.90%-196.43%
EBITDA
-22.98-19.6-13.65-17.78-13.89-
EBITDA Margin
-70.10%-62.08%-37.05%-173.17%-251.87%-
D&A For EBITDA
1.281.010.820.340.09-
EBIT
-24.25-20.61-14.47-18.12-13.99-6.1
EBIT Margin
-74.00%-65.27%-39.29%-176.51%-253.57%-197.67%
Revenue as Reported
34.2134.2139.7411.177.243.1
Source: S&P Global Market Intelligence. Standard template. Financial Sources.